Kisspeptin-10 Research: What 535 Studies Show (2026) | RetatrutideCompare

Kisspeptin-10 — 535 studies indexed on PubMed. Activates the GPR54 (KISS1R) receptor on hypothalamic GnRH neurons, driving GnRH and downstream LH/FSH release. Half-life: ~4 minutes. FDA status: Investigational.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Kisspeptin-10?

There are approximately 535 studies indexed on PubMed that mention Kisspeptin-10 (Metastin (45-54), KP-10), based on a search last updated 2026-06-18.

Is Kisspeptin-10 FDA-approved?

FDA status: Investigational.

How does Kisspeptin-10 work?

Activates the GPR54 (KISS1R) receptor on hypothalamic GnRH neurons, driving GnRH and downstream LH/FSH release.

Reference facts

Also known as: Metastin (45-54), KP-10
Category: Sexual Health & MSH
Mechanism of action: Activates the GPR54 (KISS1R) receptor on hypothalamic GnRH neurons, driving GnRH and downstream LH/FSH release.
Targets: KISS1R / GPR54
Indications under research or approved: Research — hypothalamic amenorrhea, IVF trigger, male hypogonadism
Regulatory status (reference entry): Investigational
Half-life: ~4 minutes
Sequence: YNWNSFGLRF
Sequence notes: Decapeptide C-terminal active fragment of human kisspeptin (full peptide 54 aa). C-terminal amide.
Molecular weight (Da): 1302
First reported: 2001

Primary References

Skorupskaite et al., Hum Reprod Update 2014 (Kisspeptin)

Explore research articles about Kisspeptin-10

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.